CDP-Choline

CDP-choline, known generically as citicoline, is a nucleotide compound that occurs naturally in the cells of the body, where it is a key intermediate in the Kennedy pathway that builds phosphatidylcholine, one of the main phospholipids of neuronal membranes ^[3]. When taken by mouth it is broken down and absorbed as its two components, choline and cytidine, which readily cross into the brain and are used to make membrane phospholipids and the neurotransmitter acetylcholine ^[3].

Citicoline has been studied for several neurological purposes. Reviews describe neuroprotective and anti-inflammatory actions and potential benefits in age-related memory decline, and some clinical trials in stroke and post-stroke cognitive impairment have reported improvements in attention and recovery ^[1][4]. The evidence, however, is mixed; the largest stroke trials and pooled analyses did not find a clear benefit for survival or overall recovery, so its role after stroke remains debated ^[1]. It has also been examined as a nootropic for focus and attention and for helping to protect vision in glaucoma ^[3].

Mechanistically, citicoline is thought to work by stabilizing cell membranes and supporting their repair, by supplying choline for acetylcholine synthesis, and by reducing the release of the excitatory neurotransmitter glutamate along with free radicals and inflammatory mediators after injury ^[1][3]. It is well absorbed, has high oral bioavailability, and is generally regarded as having low toxicity ^[3]. In many countries citicoline is sold as a prescription drug for neurological conditions, while in the United States it is marketed as an over-the-counter dietary supplement ^[3].

Citicoline is available in oral tablets and capsules, as a sodium salt, and in injectable forms used in some clinical settings. Reported side effects are typically mild and may include stomach upset and diarrhea ^[2][4].

CDP-Choline goes down easy at normal doses and sells OTC as a supplement in the US and most places; in parts of Europe, Japan, and South America it's a prescription drug (Somazina) with a strong clinical track record. Healthy adults don't have much to worry about. The one theoretical flag is possible antagonism with levodopa or dopamine precursors, though the human evidence for that is shaky. Piling on too much choline can tip susceptible people into low mood because of a hypercholinergic state, so if you have a history of depression or bipolar, start low and watch how you feel. Not scheduled anywhere. Take it earlier in the day so it doesn't cut into sleep.

The best-documented interaction for CDP-choline (citicoline) is with levodopa: clinical studies in Parkinson disease found that adding citicoline potentiated the response to levodopa and allowed the levodopa dose to be reduced while maintaining symptom control. This is a pharmacodynamic potentiation of dopaminergic therapy rather than a metabolic interaction. Beyond the levodopa data, citicoline has a limited documented interaction profile; a theoretical concern is opposition to central anticholinergic agents given its role as a cholinergic precursor, but this is not established clinically. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Cytidine diphosphate-choline was first characterized as a natural metabolic intermediate through the work of Eugene Kennedy in the 1950s, who mapped the pathway (now called the Kennedy pathway) by which cells assemble phosphatidylcholine. As a therapeutic, citicoline was developed and introduced in Japan, initially studied for stroke recovery and head trauma, and it later became a widely used prescription medicine across parts of Europe and Asia under brand names such as Somazina and Ceraxon. In the United States it is instead sold as an over-the-counter dietary supplement, a status it reached in the 2000s, with the branded ingredient Cognizin being a common form. Its dual identity as both a prescription drug and a supplement, depending on jurisdiction, remains one of its defining regulatory features.

Citicoline enjoys a solid reputation among clinicians and supplement users as one of the better-studied cholinergic compounds, valued for supplying both choline for acetylcholine synthesis and cytidine for membrane phospholipid repair. It has attracted particular interest for age-related memory complaints, stroke rehabilitation, and glaucoma, and it is often favored for its long safety record and good tolerability.

Recent reviews continue to describe encouraging signals for vascular and post-stroke cognitive impairment, and one systematic review noted improvements in declarative memory and verbal learning. In fairness, the clinical evidence base is genuinely mixed; large trials such as ICTUS in acute stroke did not confirm benefit, and results across cognitive indications have been inconsistent. It is best viewed as a well-tolerated, mechanistically sensible option rather than a proven cure.